Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27

Amneal Pharmaceuticals, Inc.

2026-Q1 EPS reported $0.19 revenue$722,519,000

Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.
Adjusted EBITDA $202M (+19% YoY); adjusted diluted EPS $0.27 (+29% vs. $0.21).
Specialty revenue +23% driven by CREXONT, BREKIYA autoinjector, and UNITHROID; Affordable Medicines +2%.
AvKARE revenue -4% as government channel growth offset decline in low-margin distribution.
Affirms previously announced increase in full year 2026 guidance; results matched preliminary numbers from April 22.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $723 million, net income $62 million, EPS $0.19. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $723 million
Net income: $62 million
EPS: $0.19
Guidance: reaffirmed
Result: reported results

Exact text from the filing

AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.